Moody Aldrich Partners LLC Grows Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Moody Aldrich Partners LLC boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 110.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 46,312 shares of the company's stock after purchasing an additional 24,290 shares during the quarter. Moody Aldrich Partners LLC owned about 0.14% of TransMedics Group worth $3,655,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of TransMedics Group by 1.7% in the third quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company's stock valued at $99,341,000 after buying an additional 29,798 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of TransMedics Group by 271.2% in the third quarter. American Century Companies Inc. now owns 486,956 shares of the company's stock valued at $26,661,000 after buying an additional 355,755 shares in the last quarter. Eagle Health Investments LP lifted its stake in shares of TransMedics Group by 78.5% in the third quarter. Eagle Health Investments LP now owns 414,205 shares of the company's stock valued at $22,678,000 after buying an additional 182,173 shares in the last quarter. Qube Research & Technologies Ltd lifted its stake in shares of TransMedics Group by 31.2% in the third quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company's stock valued at $4,624,000 after buying an additional 20,081 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in shares of TransMedics Group by 17.8% in the third quarter. Sei Investments Co. now owns 386,082 shares of the company's stock valued at $21,139,000 after buying an additional 58,269 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Piper Sandler assumed coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They set an "overweight" rating and a $95.00 price target on the stock. Morgan Stanley raised their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. raised their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an "overweight" rating in a research report on Tuesday, February 27th. Finally, Oppenheimer lifted their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus target price of $102.00.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 4,947 shares of the company's stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $80.36, for a total transaction of $397,540.92. Following the sale, the insider now owns 25,185 shares of the company's stock, valued at approximately $2,023,866.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Tamer I. Khayal sold 2,330 shares of the stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total value of $209,909.70. Following the transaction, the insider now owns 14,375 shares of the company's stock, valued at approximately $1,295,043.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Tamer I. Khayal sold 4,947 shares of the stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $80.36, for a total transaction of $397,540.92. Following the completion of the transaction, the insider now directly owns 25,185 shares in the company, valued at approximately $2,023,866.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 97,896 shares of company stock valued at $8,062,360. Company insiders own 6.70% of the company's stock.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX traded up $3.30 during midday trading on Tuesday, hitting $93.24. The company's stock had a trading volume of 1,231,197 shares, compared to its average volume of 671,572. The stock has a fifty day moving average price of $82.27 and a 200 day moving average price of $71.17. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $99.63. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of -119.49 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.22. The business had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group's revenue was up 158.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.21) EPS. On average, research analysts forecast that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.